Every 8-K that Brainstorm Cell Therapeutics I (BCLI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BCLI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCLI filings page.
BrainStorm Cell Therapeutics Inc. reported second quarter 2026 results and provided a corporate update centered on its NurOwn autologous stem cell platform for ALS and other neurodegenerative diseases. The company is completing preparations to initiate the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment.
Peter Pitts, a former senior FDA official, has been appointed Executive Chairman with an active role in regulatory, operational, partnership and capital-markets initiatives. NurOwn has Orphan Drug designation in the U.S. and EU, with a completed Phase 3 ALS trial and a Phase 2 trial in progressive multiple sclerosis. BrainStorm is also advancing an allogeneic exosome-based platform and recently received a Notice of Allowance for a foundational exosome patent.
Financially, total assets were $788 thousand as of June 30, 2026, versus liabilities of $12,385 thousand, resulting in stockholders’ deficit of $(11,597) thousand. Cash and cash equivalents were $22 thousand$3,855 thousand (basic and diluted net loss per share of $0.35) compared with a net loss of $2,903 thousand a year earlier.
BrainStorm Cell Therapeutics reports significant leadership and compensation changes. The board appointed director Peter Pitts as Executive Chairman and Chief Strategic Regulatory and Policy Officer, granting him stock options for 900,000 common shares; he will not receive base salary, cash bonus, or director compensation. One-fourth of this option vests on July 24, 2027, with the remainder vesting in equal monthly installments over the following three years.
Professor Jacob Frenkel resigned as chairman and director, will serve as an advisor under a consulting agreement, and received 100,000 restricted stock units vesting in two tranches through April 24, 2027, along with accelerated vesting and extended exercise periods for his options; his resignation was not due to any disagreement. Executive Vice President and Chief Medical Officer Ibrahim Dagher resigned and will consult for one year under an agreement that treats his service as continued employment for equity awards and, upon successful completion, fully vests his outstanding equity and extends option exercise periods. A company press release highlights Pitts’s role in leading the planned NurOwn Phase 3b ALS trial under an FDA Special Protocol Assessment.
Brainstorm Cell Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Peter Pitts as a director effective May 25, 2026, to serve until the company’s 2026 Annual Meeting of Stockholders and until his successor is elected and qualified.
Pitts, age 67, brings over 30 years of health care public policy experience, including prior service as Associate Commissioner of the U.S. Food & Drug Administration and President of the Center for Medicine in the Public Interest. Upon appointment, he received an option to purchase up to 150,000 shares of common stock, with half vesting immediately and half on the six-month anniversary of issuance. The Board determined he is independent under applicable SEC rules, and the company plans to enter into a standard director indemnification agreement with him.
BrainStorm Cell Therapeutics reported first quarter 2026 results and updated progress on its NurOwn ALS program. For the three months ended March 31, 2026, the company recorded a net loss of $2,127 thousand, narrower than the $2,864 thousand loss a year earlier, with a basic and diluted net loss per share of $0.19.
Research and development expenses were $762 thousand and general and administrative expenses were $1,284 thousand. The balance sheet shows cash and cash equivalents of $15 thousand and total assets of $755 thousand versus total liabilities of $11,764 thousand, resulting in stockholders’ deficit of $11,009 thousand as of March 31, 2026.
Management highlighted preparations for the planned Phase 3 ENDURANCE study of NurOwn in ALS, noting that site activation, manufacturing readiness, and regulatory engagement are progressing and that moving into enrollment remains subject to securing the necessary financing.
BrainStorm Cell Therapeutics Inc. reported full-year 2025 results and a corporate update, highlighting a strategic $2.0 million post–year-end financing to support its NurOwn ALS program and planned Phase 3b confirmatory study under a Special Protocol Assessment with the FDA.
For 2025, the company recorded a net loss of $10.3 million, or $1.11 per share, with operating expenses of $4.2 million for research and development and $5.8 million for general and administrative activities. At December 31, 2025, cash and cash equivalents were $29,000, total assets were $1.0 million, and total liabilities were $11.0 million, resulting in a stockholders’ deficit of $10.0 million.
Brainstorm Cell Therapeutics Inc. entered a Securities Purchase Agreement with an accredited investor for up to $1,000,000 in a private placement of common stock and pre-funded warrants, to be completed in up to eight closings. The first closing on February 24, 2026 delivered $125,000, with up to $875,000 remaining at investor-determined timings.
Securities are priced at $0.60 per share, with pre-funded warrants priced at $0.60 less $0.0005 and exercisable at $0.00005 per share. The company will also issue common warrants exercisable at $1.00 for 120% of the shares and pre-funded warrants purchased. Proceeds are earmarked for working capital, and the company committed to register the resale of these securities and to maintain its stock market listing.
The board also approved amendments to its 2014 stock and global option plans, increasing the shared equity pool by 5,500,000 shares to a total of 8,406,666 shares of common stock available for equity awards to employees, officers and directors.
Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement for a $1,000,000 private placement of common stock and pre-funded warrants with an accredited investor, split into two closings of $500,000 each at a purchase price of $0.60 per share.
The investor may instead receive pre-funded warrants priced at $0.60 less $0.0005, with an exercise price of $0.00005 per share, to stay within beneficial ownership limits of 4.99% or 9.99%. The company will also issue common stock purchase warrants exercisable at $1.00 per share for 120% of the shares and pre-funded warrants purchased.
The first closing occurred on February 9, 2026, with the second scheduled 30 days later under the agreement’s conditions. Brainstorm Cell plans to use the net proceeds for working capital and has committed to register the resale of the securities and maintain the listing of its common stock and warrant shares.
Brainstorm Cell Therapeutics Inc. entered into three short-term financing deals through unsecured promissory and convertible notes with institutional investors. On December 31, 2025, it issued a note with a principal amount of $94,300 to Vanquish Funding Group Inc., receiving $82,000 in proceeds and allowing for additional tranches of up to $2,000,000 subject to further agreement. On January 5, 2026, it issued a $94,875 convertible note to Quick Capital, LLC for approximately $80,000 in proceeds. On January 6, 2026, it issued a $140,000 convertible note to Auctus Fund, LLC for $126,000 in cash proceeds before fees.
The notes carry one-time interest charges of 10% or 12%, fixed maturities around 12 months, and scheduled amortization payments. Conversion to common stock is generally at a discount to recent trading prices, subject to a 4.99% beneficial ownership cap, with higher conversion rights or penalties triggered by events of default. The Auctus agreement also includes piggy-back registration rights, a most favored nation provision, prohibitions on certain variable rate deals, and a right to apply portions of future financings to repayment.
Brainstorm Cell Therapeutics (BCLI) entered a Securities Purchase Agreement with Labrys Fund II, L.P. and issued a promissory note with $143,750 principal (including $18,750 original issue discount). The Company received $121,500 in funds after $3,500 in legal fees. The note is convertible upon an event of default into common stock at a 25% discount to the lowest trading price over the prior 20 trading days, subject to a 4.99% beneficial ownership limit.
Scheduled payments of $22,589 are due on May 11, June 10, July 10, August 10, September 10, and October 9, 2026, with the remaining balance due at maturity on November 10, 2026. The note and any conversion shares are being issued in a private placement exempt from registration under Section 4(a)(2). The Company also announced financial results for the quarter ended September 30, 2025 via a press release furnished as an exhibit.
Brainstorm Cell Therapeutics entered a securities purchase agreement with Vanquish Funding Group and issued a promissory note with $182,400 principal (including $22,400 original issue discount). The Company received $155,000 in funds after $5,000 in combined legal and due diligence fees.
The Note bears 12% interest, increasing to 22% if not timely paid, and matures on August 30, 2026. Scheduled payments are $102,144 on April 30, 2026 and $25,536 on each of May 30, 2026, June 30, 2026, July 30, 2026, and August 30, 2026. Upon an event of default, the Note is convertible into common stock at a 35% discount to the lowest trading price over the prior 10 trading days, subject to a 4.99% beneficial ownership limitation.
The agreement provides that, subject to further agreement between the parties, Vanquish may offer additional financing tranches over the next 12 months of up to $2,000,000 in aggregate. Conversion shares, if issued under the Note, are intended to be exempt from registration under Section 4(a)(2).
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) filed a Form 8-K summarizing the results of its June 25, 2025 virtual Annual Meeting of Stockholders. Shareholders approved Amendment No. 5 to both the 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, expanding the shared equity pool by 2,000,000 shares to a total of 2,906,666 shares. Company officers and directors remain eligible to receive awards under the enlarged pool.
All seven director nominees—Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino, Uri Yablonka and Dr. Stacy Lindborg—were re-elected, with votes “FOR” ranging from 958,146 to 1,055,967 and 2,556,446 broker non-votes on each slate. Shareholders also ratified Deloitte-affiliate Brightman Almagor Zohar & Co. as independent auditor for FY-2025 (3,346,891 “FOR” versus 315,162 “AGAINST”).
In addition, investors approved (i) Nasdaq Rule 5635(d) clearance to issue shares underlying a Common Warrant potentially exceeding 20% of current outstanding shares (874,965 “FOR”) and (ii) the aforementioned share-reserve increase (758,668 “FOR”, 362,809 “AGAINST”). No financial statements were presented; the filing is limited to governance and equity-compensation matters. The new equity authorizations could be dilutive if fully exercised, but they provide the company with added flexibility to reward personnel and fund future growth initiatives.